Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H19N5 |
Molecular Weight | 293.3669 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C#N)c1cc(cc(c1)C(C)(C)C#N)Cn2cncn2
InChI
InChIKey=YBBLVLTVTVSKRW-UHFFFAOYSA-N
InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
Molecular Formula | C17H19N5 |
Molecular Weight | 293.3669 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Anastrozole (marketed under the trade name Arimidex by AstraZeneca) is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens. The growth of many cancers of the breast is stimulated or maintained by estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19794821 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ARIMIDEX Approved UseAnastrozole is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole ( 1.3) 1.1 Adjuvant Treatment Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. 1.2 First-Line Treatment Anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. 1.3 Second-Line Treatment Anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. Launch Date8.2002241E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
39.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19470631 |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ANASTROZOLE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
648 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19470631 |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ANASTROZOLE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
yes [Ki 10 uM] | ||||
yes [Ki 10 uM] | ||||
yes [Ki 8 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
low | ||||
low | ||||
low | ||||
major | ||||
major | ||||
minor | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Pure antiestrogens and breast cancer. | 2001 |
|
New combinations with Herceptin in metastatic breast cancer. | 2001 |
|
Fulvestrant. | 2001 |
|
[Modern approaches to hormone therapy of breast cancer as a reflection of pathogenesis of the disease]. | 2001 |
|
Update on endocrine aspects of breast cancer: report from the 23rd San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 6-9 December 2000. | 2001 |
|
The Twenty-third Annual San Antonio Breast Cancer Symposium. | 2001 |
|
Breast cancer chemoprevention: beyond tamoxifen. | 2001 |
|
[Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies]. | 2001 Apr |
|
Estrogenic upregulation of DNA polymerase beta in oocytes of preovulatory ovine follicles. | 2001 Apr |
|
Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure. | 2001 Aug |
|
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. | 2001 Aug 3 |
|
Promising results for Arimidex and Femara. | 2001 Dec |
|
The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients. | 2001 Dec |
|
Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer. | 2001 Dec |
|
Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy. | 2001 Dec |
|
A summary of second-line randomized studies of aromatase inhibitors. | 2001 Dec |
|
[Endometriosis and aromatase inhibitor]. | 2001 Jan |
|
Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. | 2001 Jan |
|
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. | 2001 Jan-Mar |
|
[Endocrine therapy for advanced or recurrent breast cancer]. | 2001 Jul |
|
[Developments of hormonal agents for breast cancer]. | 2001 Jul |
|
Pharmacokinetics of anastrozole in Chinese male volunteers. | 2001 Jun |
|
Endocrine therapy in the treatment of metastatic breast cancer. | 2001 Jun |
|
The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. | 2001 Jun |
|
Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men. | 2001 Jun |
|
The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. | 2001 May |
|
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer]. | 2001 May |
|
Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. | 2001 May |
|
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. | 2001 May |
|
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? | 2001 May 1 |
|
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? | 2001 May 1 |
|
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? | 2001 May 1 |
|
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? | 2001 May 1 |
|
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? | 2001 May 1 |
|
Aromatase inhibitors and arthralgia. | 2001 May 15 |
|
ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data. | 2001 Nov |
|
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. | 2001 Nov 1 |
|
Role of anti-aromatase agents in postmenopausal advanced breast cancer. | 2001 Oct |
|
Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. | 2001 Oct 15 |
|
Aromatase inhibitors and inactivators in breast cancer. | 2001 Oct 20 |
|
Recent advances in breast cancer (the Twenty-fourth San Antonio Breast Cancer Symposium, December, 2001). | 2002 |
|
Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer. | 2002 |
|
Existing and emerging endocrine therapies for breast cancer. | 2002 Apr |
|
Antiaromatase agents: evolving role in adjuvant therapy. | 2002 Apr |
|
World's largest breast cancer treatment trial supports anastrozole use. | 2002 Jan |
|
Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact. | 2002 Jul 1 |
|
Letrozole for the management of breast cancer. | 2002 Jun |
|
Efficacy of anastrozole in male breast cancer. | 2002 Jun |
|
Aromatase inhibition for ovarian stimulation: future avenues for infertility management. | 2002 Jun |
|
A better medication for treating breast cancer? | 2002 May |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25839436
Anastrozole, aromatase inhibitor was added at a concentration of 200 and 300 μg/mL to the endometrioma cells. The use of anastrozole significantly inhibited the growth of endometrioma cells, and estradiol secretion.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:04:22 UTC 2021
by
admin
on
Fri Jun 25 21:04:22 UTC 2021
|
Record UNII |
2Z07MYW1AZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175563
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
||
|
WHO-VATC |
QL02BG03
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
||
|
WHO-ATC |
L02BG03
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
||
|
NCI_THESAURUS |
C2018
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
||
|
NDF-RT |
N0000175080
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
||
|
LIVERTOX |
56
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
120511-73-1
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
DB01217
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
7462
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
5137
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
2187
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
210
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
SUB05502MIG
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
120511-73-1
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
2Z07MYW1AZ
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
CHEMBL1399
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
1034807
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | USP-RS | ||
|
7274
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
84857
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | RxNorm | ||
|
M1889
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | Merck Index | ||
|
ANASTROZOLE
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
C1607
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY | |||
|
C090450
Created by
admin on Fri Jun 25 21:04:23 UTC 2021 , Edited by admin on Fri Jun 25 21:04:23 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
lacks pharmacologic activity
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||